NZ603136A - Bifunctional quinoline derivatives - Google Patents
Bifunctional quinoline derivativesInfo
- Publication number
- NZ603136A NZ603136A NZ603136A NZ60313611A NZ603136A NZ 603136 A NZ603136 A NZ 603136A NZ 603136 A NZ603136 A NZ 603136A NZ 60313611 A NZ60313611 A NZ 60313611A NZ 603136 A NZ603136 A NZ 603136A
- Authority
- NZ
- New Zealand
- Prior art keywords
- hydroxy
- bifunctional
- quinoline derivatives
- dihydroquinolin
- methylquinoline
- Prior art date
Links
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title 1
- 230000001588 bifunctional effect Effects 0.000 title 1
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- RHAQDHOXCGXPBG-LHEWISCISA-N 6-[3-[8-[[(2r)-2-hydroxy-2-(8-hydroxy-2-oxo-1h-quinolin-5-yl)ethyl]amino]octylcarbamoyl]phenyl]sulfonyl-4-(3-methoxyanilino)-8-methylquinoline-3-carboxamide Chemical compound COC1=CC=CC(NC=2C3=CC(=CC(C)=C3N=CC=2C(N)=O)S(=O)(=O)C=2C=C(C=CC=2)C(=O)NCCCCCCCCNC[C@H](O)C=2C=3C=CC(=O)NC=3C(O)=CC=2)=C1 RHAQDHOXCGXPBG-LHEWISCISA-N 0.000 abstract 1
- 206010006482 Bronchospasm Diseases 0.000 abstract 1
- 206010035664 Pneumonia Diseases 0.000 abstract 1
- 230000007885 bronchoconstriction Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33302010P | 2010-05-10 | 2010-05-10 | |
| US40693010P | 2010-10-26 | 2010-10-26 | |
| US201161477263P | 2011-04-20 | 2011-04-20 | |
| PCT/US2011/035738 WO2011143105A1 (en) | 2010-05-10 | 2011-05-09 | Bifunctional quinoline derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ603136A true NZ603136A (en) | 2014-11-28 |
Family
ID=44072535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ603136A NZ603136A (en) | 2010-05-10 | 2011-05-09 | Bifunctional quinoline derivatives |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US8394829B2 (enExample) |
| EP (1) | EP2569285A1 (enExample) |
| JP (2) | JP5807058B2 (enExample) |
| AR (1) | AR081026A1 (enExample) |
| AU (1) | AU2011253203A1 (enExample) |
| CA (1) | CA2796826A1 (enExample) |
| NZ (1) | NZ603136A (enExample) |
| UY (1) | UY33372A (enExample) |
| WO (1) | WO2011143105A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2796826A1 (en) * | 2010-05-10 | 2011-11-17 | Gilead Sciences, Inc. | Bifunctional quinoline derivatives |
| EA201591360A1 (ru) | 2013-02-19 | 2016-03-31 | Пфайзер Инк. | Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств |
| WO2015119998A1 (en) * | 2014-02-06 | 2015-08-13 | Abbvie, Inc. | 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof |
| JP6125467B2 (ja) * | 2014-06-16 | 2017-05-10 | 富士フイルム株式会社 | プリント注文受付機とその作動方法および作動プログラム |
| EP3172210B1 (en) | 2014-07-24 | 2020-01-15 | Pfizer Inc | Pyrazolopyrimidine compounds |
| AU2015298378B2 (en) | 2014-08-06 | 2018-08-02 | Pfizer Inc. | Imidazopyridazine compounds |
| CN118286245A (zh) | 2014-12-26 | 2024-07-05 | 埃莫里大学 | N4-羟基胞苷和衍生物及与其相关的抗病毒用途 |
| CN106554350B (zh) * | 2015-09-29 | 2019-12-20 | 四川海思科制药有限公司 | 具有β2激动活性的苯并杂环衍生物及其制法和应用 |
| WO2017089347A1 (en) | 2015-11-25 | 2017-06-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas |
| RS66222B1 (sr) | 2017-12-07 | 2024-12-31 | Univ Emory | N4-hidroksicitidin i derivati i antivirusne upotrebe povezane sa njim |
| CN112250557A (zh) * | 2020-10-23 | 2021-01-22 | 徐州工程学院 | 一种高效合成1,6-二烯-3-酮衍生物的方法 |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3361306A (en) | 1966-03-31 | 1968-01-02 | Merck & Co Inc | Aerosol unit dispensing uniform amounts of a medically active ingredient |
| US3565070A (en) | 1969-02-28 | 1971-02-23 | Riker Laboratories Inc | Inhalation actuable aerosol dispenser |
| US3885047A (en) | 1972-06-16 | 1975-05-20 | Mead Johnson & Co | Ocular hypotensive process employing dextrorotatory phenethanolamines |
| US4145542A (en) | 1974-06-13 | 1979-03-20 | Otsuka Pharmaceutical Co., Ltd. | 5- 1-Hydroxy-2-(heterocyclic-amino)!alkyl-8-hydroxy-3,4-dihydrocarbostyril derivatives |
| ZW6584A1 (en) | 1983-04-18 | 1985-04-17 | Glaxo Group Ltd | Phenethanolamine derivatives |
| US4805811A (en) | 1985-03-29 | 1989-02-21 | Aktiebolaget Draco | Dosage device |
| US4761421A (en) | 1985-05-08 | 1988-08-02 | Merck & Co., Inc. | Use of certain compounds in livestock food as growth promotants for better feed utilization and improved carcass composition |
| US4955371A (en) | 1989-05-08 | 1990-09-11 | Transtech Scientific, Inc. | Disposable inhalation activated, aerosol device for pulmonary medicine |
| DE4003272A1 (de) | 1990-02-03 | 1991-08-08 | Boehringer Ingelheim Kg | Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen |
| GB9107196D0 (en) | 1991-04-05 | 1991-05-22 | Sandoz Ag | Improvements in or relating to organic compounds |
| CA2112674C (en) | 1991-07-02 | 2005-10-04 | John S. Patton | Method and device for delivering aerosolized medicaments |
| EP0617610B1 (en) | 1991-12-18 | 1997-03-19 | Minnesota Mining And Manufacturing Company | Suspension aerosol formulations |
| US7105152B1 (en) | 1991-12-18 | 2006-09-12 | 3M Innovative Properties Company | Suspension aerosol formulations |
| US5261538A (en) | 1992-04-21 | 1993-11-16 | Glaxo Inc. | Aerosol testing method |
| US5455252A (en) | 1993-03-31 | 1995-10-03 | Syntex (U.S.A.) Inc. | Optionally substituted 6,8-quinolines |
| SI0706513T1 (en) | 1993-07-02 | 2002-10-31 | Altana Pharma Ag | Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors |
| US5776983A (en) | 1993-12-21 | 1998-07-07 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
| US5522385A (en) | 1994-09-27 | 1996-06-04 | Aradigm Corporation | Dynamic particle size control for aerosolized drug delivery |
| US5544647A (en) | 1994-11-29 | 1996-08-13 | Iep Group, Inc. | Metered dose inhalator |
| US5622163A (en) | 1994-11-29 | 1997-04-22 | Iep Group, Inc. | Counter for fluid dispensers |
| SK284448B6 (sk) | 1995-04-14 | 2005-04-01 | Glaxo Wellcome Inc. | Merací dávkovací inhalátor |
| AU5772196A (en) | 1995-05-19 | 1996-11-29 | Chiroscience Limited | 3,4-disubstituted-phenylsulphonamides and their therapeutic use |
| GB9523267D0 (en) | 1995-11-14 | 1996-01-17 | Sandoz Ltd | Organic compounds |
| JP2000510866A (ja) | 1996-05-20 | 2000-08-22 | ダーウィン・ディスカバリー・リミテッド | Ｔｎｆとｐｄｅ―ｉｖのインヒビターとしてのキノリンスルホンアミド |
| IL126557A (en) | 1996-05-20 | 2002-09-12 | Darwin Discovery Ltd | Quinoline (thio) carboxamides inhibiting TNF or PDE-IV and pharmaceutical preparations containing them |
| GB9712761D0 (en) | 1997-06-17 | 1997-08-20 | Chiroscience Ltd | Quinolines and their therapeutic use |
| US6069151A (en) | 1996-11-06 | 2000-05-30 | Darwin Discovery, Ltd. | Quinolines and their therapeutic use |
| US20010031244A1 (en) | 1997-06-13 | 2001-10-18 | Chiesi Farmaceutici S.P.A. | Pharmaceutical aerosol composition |
| GB9807232D0 (en) | 1998-04-03 | 1998-06-03 | Univ Cardiff | Aerosol composition |
| CZ293735B6 (cs) * | 1998-08-26 | 2004-07-14 | Smithkline Beecham Corporation | Farmaceutický prostředek pro léčbu plicní nemoci |
| US6262070B1 (en) | 1998-11-04 | 2001-07-17 | Darwin Discovery Ltd. | Heterocyclic compounds and their therapeutic use |
| US6329034B1 (en) | 1999-01-18 | 2001-12-11 | Roger L. Pendry | Label having tab member and methods for forming, applying and using the same |
| US6116234A (en) | 1999-02-01 | 2000-09-12 | Iep Pharmaceutical Devices Inc. | Metered dose inhaler agitator |
| ES2241611T3 (es) | 1999-06-05 | 2005-11-01 | Innovata Biomed Limited | Sisstema de suministro de medicamentos. |
| GB2353222B (en) | 1999-06-23 | 2001-09-19 | Cambridge Consultants | Inhalers |
| SI1212089T1 (sl) | 1999-08-21 | 2006-08-31 | Altana Pharma Ag | Sinergisticna kombinacija roflumilasta in salmeterola |
| GB9920839D0 (en) | 1999-09-04 | 1999-11-10 | Innovata Biomed Ltd | Inhaler |
| WO2001026720A1 (en) | 1999-10-12 | 2001-04-19 | Shl Medical Ab | Inhaler |
| GB9928265D0 (en) | 1999-12-01 | 2000-01-26 | Innovata Biomed Ltd | Inhaler |
| AU8030500A (en) | 1999-12-08 | 2001-06-18 | Qualcomm Incorporated | Monitoring user interaction with web advertisements |
| SE9904706D0 (sv) | 1999-12-21 | 1999-12-21 | Astra Ab | An inhalation device |
| US6410563B1 (en) | 1999-12-22 | 2002-06-25 | Merck Frosst Canada & Co. | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors |
| US7171965B2 (en) | 2000-02-01 | 2007-02-06 | Valois S.A.S. | Breath actuated dry powder inhaler and tape dose strip |
| KR20030031907A (ko) | 2000-06-05 | 2003-04-23 | 알타나 파마 아게 | β-2-아드레날린 수용체 작동물질로서 뿐만 아니라ＰＤＥ4-억제제로서 효과적인 화합물 |
| FR2813593B1 (fr) | 2000-09-07 | 2002-12-06 | Valois Sa | Dispositif de distribution de produit fluide de type multidose |
| GB0026647D0 (en) | 2000-10-31 | 2000-12-13 | Glaxo Group Ltd | Medicament dispenser |
| US6740666B2 (en) | 2000-12-20 | 2004-05-25 | Merck & Co., Inc. | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors |
| US6919353B2 (en) | 2001-06-27 | 2005-07-19 | Merck Frosst Canada & Co. | Substituted 8-arylquinolune PDE4 inhibitors |
| US6858615B2 (en) | 2002-02-19 | 2005-02-22 | Parion Sciences, Inc. | Phenyl guanidine sodium channel blockers |
| ATE432261T1 (de) | 2002-03-18 | 2009-06-15 | Merck Frosst Canada Ltd | Pde4-inhibitoren mit heterobrückensubstituiertem 8-arylchinolin |
| US6889690B2 (en) | 2002-05-10 | 2005-05-10 | Oriel Therapeutics, Inc. | Dry powder inhalers, related blister devices, and associated methods of dispensing dry powder substances and fabricating blister packages |
| JP2005527618A (ja) * | 2002-05-28 | 2005-09-15 | セラヴァンス インコーポレーテッド | アルコキシアリールβ２アドレナリン作動性レセプターアゴニスト |
| AU2003243870B2 (en) | 2002-06-25 | 2008-11-20 | Merck Frosst Canada Ltd | 8-(biaryl) quinoline PDE4 inhibitors |
| WO2004047836A1 (en) | 2002-11-22 | 2004-06-10 | Merck Frosst Canada & Co. | Use of phosphodiesterase-4 inhibitors as enhancers of cognition |
| US6903105B2 (en) | 2003-02-19 | 2005-06-07 | Parion Sciences, Inc. | Sodium channel blockers |
| WO2004096220A1 (en) | 2003-04-30 | 2004-11-11 | Merck Frosst Canada Ltd. | 8-(3-biaryl)phenylquinoline phosphodiesterase-4-inhibitors |
| TWI328009B (en) | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
| EP1488819A1 (en) | 2003-06-16 | 2004-12-22 | Rijksuniversiteit te Groningen | Dry powder inhaler and method for pulmonary inhalation of dry powder |
| EP1663235B1 (en) | 2003-08-18 | 2013-07-24 | Parion Sciences, Inc. | Capped pyrazinoylguanidine sodium channel blockers |
| GB0322722D0 (en) | 2003-09-27 | 2003-10-29 | Glaxo Group Ltd | Compounds |
| GB0322726D0 (en) | 2003-09-27 | 2003-10-29 | Glaxo Group Ltd | Compounds |
| WO2006023460A2 (en) * | 2004-08-16 | 2006-03-02 | Theravance, Inc. | COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY |
| US7399766B2 (en) | 2004-08-18 | 2008-07-15 | Parion Sciences, Inc. | Soluble amide & ester pyrazinoylguanidine sodium channel blockers |
| GB0503955D0 (en) | 2005-02-25 | 2005-04-06 | Glaxo Group Ltd | Novel compounds |
| ES2332290T3 (es) | 2005-08-01 | 2010-02-01 | Chiesi Farmaceutici S.P.A. | Formulaciones farmaceuticas que comprenden un agonista de beta2 de accion prolongada para su administracion mediante nebulizacion. |
| US7807834B2 (en) | 2005-08-03 | 2010-10-05 | Parion Sciences, Inc. | Capped pyrazinoylguanidine sodium channel blockers |
| US20100004215A1 (en) | 2005-10-19 | 2010-01-07 | Abhijit Ray | Compositions of phosphodiesterase type iv inhibitors |
| RU2464973C2 (ru) | 2006-01-24 | 2012-10-27 | НексБио, Инк. | Технология изготовления макромолекулярных микросфер |
| JP2009118740A (ja) | 2006-03-03 | 2009-06-04 | Ajinomoto Co Inc | Ｌ−アミノ酸の製造法 |
| GB0605462D0 (en) | 2006-03-17 | 2006-04-26 | Glaxo Group Ltd | Novel compounds |
| NZ570693A (en) * | 2006-03-20 | 2011-02-25 | Pfizer Ltd | Amine derivatives |
| SI2035004T1 (sl) | 2006-06-09 | 2012-12-31 | Parion Sciences, Inc. | S fenilom substituirani pirazinoilgvanidinski blokatorji natrijevih kanalov, ki imajo beta-agonistiäśno aktivnost |
| JP5280357B2 (ja) | 2006-07-07 | 2013-09-04 | スティーブン・ピー・ガベック | Ｐｄｅ４の二環式ヘテロアリール阻害剤 |
| CA2692892A1 (en) | 2007-07-24 | 2009-01-29 | Michael Malakhov | Technology for the preparation of microparticles |
| EP2249646A4 (en) | 2008-02-06 | 2013-09-25 | Glaxo Group Ltd | PDE4 muscarinic Antagonist-DOPPELPHARMACOPHOREN |
| WO2009142589A1 (en) | 2008-05-20 | 2009-11-26 | Astrazeneca Ab | Combination of (a) glucocorticoid receptor modulator and (b) a muscarinic antagonist |
| US8263623B2 (en) | 2008-07-11 | 2012-09-11 | Pfizer Inc. | Triazol derivatives useful for the treatment of diseases |
| WO2010015792A1 (en) * | 2008-08-06 | 2010-02-11 | Argenta Discovery Limited | Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors |
| UY32521A (es) | 2009-04-03 | 2010-10-29 | Astrazeneca Ab | Combinación para emplear en el tratamiento de enfermedades respiratorias |
| AR081377A1 (es) * | 2010-05-10 | 2012-08-29 | Gilead Sciences Inc | Compuestos de pirazolopiridina bifuncionales |
| CA2796826A1 (en) * | 2010-05-10 | 2011-11-17 | Gilead Sciences, Inc. | Bifunctional quinoline derivatives |
-
2011
- 2011-05-09 CA CA2796826A patent/CA2796826A1/en not_active Abandoned
- 2011-05-09 AR ARP110101593A patent/AR081026A1/es unknown
- 2011-05-09 US US13/103,577 patent/US8394829B2/en not_active Expired - Fee Related
- 2011-05-09 JP JP2013510204A patent/JP5807058B2/ja not_active Expired - Fee Related
- 2011-05-09 EP EP11719748A patent/EP2569285A1/en not_active Withdrawn
- 2011-05-09 NZ NZ603136A patent/NZ603136A/en not_active IP Right Cessation
- 2011-05-09 WO PCT/US2011/035738 patent/WO2011143105A1/en not_active Ceased
- 2011-05-09 AU AU2011253203A patent/AU2011253203A1/en not_active Abandoned
- 2011-05-09 UY UY0001033372A patent/UY33372A/es not_active Application Discontinuation
-
2012
- 2012-09-14 US US13/619,636 patent/US20130012504A1/en not_active Abandoned
-
2015
- 2015-03-09 JP JP2015045538A patent/JP2015131833A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP5807058B2 (ja) | 2015-11-10 |
| CA2796826A1 (en) | 2011-11-17 |
| JP2015131833A (ja) | 2015-07-23 |
| JP2013526520A (ja) | 2013-06-24 |
| US20110275622A1 (en) | 2011-11-10 |
| EP2569285A1 (en) | 2013-03-20 |
| AU2011253203A1 (en) | 2012-11-22 |
| AR081026A1 (es) | 2012-05-30 |
| UY33372A (es) | 2011-12-30 |
| US8394829B2 (en) | 2013-03-12 |
| WO2011143105A1 (en) | 2011-11-17 |
| US20130012504A1 (en) | 2013-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ603136A (en) | Bifunctional quinoline derivatives | |
| WO2009006389A8 (en) | Pyrimidine derivatives useful as raf kinase inhibitors | |
| WO2009158571A8 (en) | Heteroaryl compounds and uses thereof | |
| NZ600801A (en) | Substituted imidazopyridinyl-aminopyridine compounds | |
| WO2009087098A8 (en) | Quinoline derivatives and their use as fungicides | |
| AU2015205914B2 (en) | 1,6- diazabicyclo [3,2,1] octan- 7- one derivatives and their use in the treatment of bacterial infections | |
| WO2007101864A3 (en) | Compounds that modulate ppar activity, their preparation and use | |
| UA108087C2 (uk) | Тверді форми n-(4-(7-азабіцикло[2.2.1]гептан-7-іл)-2-(трифторметил)феніл)-4-оксо-5-(трифторметил)-1,4-дигідрохінолін-3-карбоксаміду | |
| WO2011153157A3 (en) | Benzoquinolone inhibitors of vmat2 | |
| WO2009079008A8 (en) | Benzopyrans and analogs as rho kinase inhibitors | |
| WO2013078259A3 (en) | Oil compositions and methods for increasing hair growth and/or preventing hair loss | |
| WO2011080568A8 (en) | Novel pyrimidine compounds as mtor and pi3k inhibitors | |
| WO2008094992A3 (en) | 2-aminopyridine derivatives useful as kinase inhibitors | |
| EP2485736A4 (en) | IMINOTHIADIAZINOXIN COMPOUNDS AS BACE HEMMER, COMPOSITIONS AND ITS USE | |
| WO2011031896A3 (en) | Pi3 kinase inhibitors and uses thereof | |
| MX2012008911A (es) | Sales y polimorfos de 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3, 4,5-tetrahidro-6h-acepino[5,4,3-cd]indol-6-ona. | |
| WO2010068292A8 (en) | Azaindole derivatives as kinase inhibitors | |
| WO2011133795A3 (en) | Beta-carbolines as inhibitors of haspin and dyrk kinases | |
| WO2011101069A3 (en) | 1, 8 -naphthyridines as kinase inhibitors | |
| WO2009132774A8 (en) | New substituted indolin-2-one derivatives and their use as p38 mitogen-activated kinase inhibitors | |
| WO2010032011A8 (en) | Anti-fungal therapy | |
| IL225704A0 (en) | Polymorphs and salts of 6-(1h-indol-4-yl)-4-(5-{[4-(1-methylethyl)-1-piperazinyl]methyl}-1,3-oxazol-2-yl)-1 h-Indazole as pi3k inhibitors for use in the treatment of respiratory problems | |
| WO2010054024A3 (en) | 1, 2 -thiazol yl derivatives as cannabinoid receptor ligands | |
| WO2011059180A3 (ko) | 탈모방지 및 두피개선을 위한 두발 화장품 조성물 | |
| WO2009094457A3 (en) | Substituted benzhydrylethers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 MAY 2016 BY AJ PARK Effective date: 20150408 |
|
| LAPS | Patent lapsed |